Discussing Shifts in the Gene Editing Landscape to Transition from Ex Vivo to In Vivo Gene Editing

  • Review the benefits of in vivo genome editing approaches from a patient perspective
  • Explore the need to refocus the safety guidelines for in vivo treatments compared to ex vivo treatments
  • Evaluate what approaches and strategies can be harnessed from ex vivo therapies to enhance in vivo therapy development